Clin Osteol 2010; 15(1): 18-25

Bone mass in patients with juvenile idiopathic arthritisInformations

K. Brábníková Marešová

Bone disease in patients with juvenile idiopathic arthritis (JIA), analogous to adults with rheumatoid arthritis, is associated with focal (joint erosion and juxta-articular osteopenia) and systemic bone loss (generalized osteopenia or reduction of bone mass density). Contrary to adult patients, in children with JIA, the disease can be complicated by growth cartilage involvement and systemic or lo­ cal growth retardation. The pathophysiology of bone loss is multifactorial, similar to that in rheumatoid arthritis, and involves parti­ cularly the effects pro-inflammatory cytokines and glucocorticoid therapy. Research findings in patients withJIA indicate excessive ac­ tivation of osteoclastogenesis and reduction of bone formation. Reduction of physical activity, muscle atrophy in the course of high disease activity and compulsory restriction in movements, decreased levels of sex hormones and dietary problems with bone loss.

Keywords: juvenile idiopathic arthritis, osteopenia/osteoporosis;fractures, growth retardation, bone remodeling, glucocorticoids

Published: June 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brábníková Marešová K. Bone mass in patients with juvenile idiopathic arthritis. Osteologický bulletin. 2010;15(1):18-25.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hanova P, Pävelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheuma­ toid arthritis, juvenile idiopathic arthritis and gout in two regions of the Cz Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol 2006;24(5):499-507.
    2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International League of Associations for Rheumatology classification ofjuvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2): 390-392.
    3. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glu corticoids. J Rheumatol 2002;29(6):1296-1300.
    4. Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL. Attained adult height in ju­ venile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 2002;21(5):363-368. Go to original source...
    5. MacRae VE, Farquharson C, Ahmed SF. The pathophysiology of the growth pla­ te in juvenile idiopathic arthritis. Rheumatology (Oxford) 2006;45(1):11-19. Go to original source...
    6. Saha MT, Haapasaari J, Hannula S, Sarna S, Lenko HL. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol 2004;31(7):1413-1417.
    7. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis: relationship with glucocorticoid therapy. Calcif Tissue Int 1987;41(2):75-78. Go to original source...
    8. Badley BW, Ansell BM. Fractures in Still's disease. Ann Rheum Dis 1960;19: 135-142. Go to original source...
    9. Burnham JM, Shults J, Weinstein R, Lewis JD, Leonard MB. Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database. Ann Rheum Dis 2006;65(8): 1074-1079. Go to original source...
    10. Ifepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bo­ ne mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996;39(5):746-757. Go to original source...
    11. Henderson CJ, Specker BL, Sierra RI, Campaigne BN, Lovell DJ. Total-body bo­ ne mineral content in non-corticosteroid-treated postpubertal females with juveni­ le rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000;43(3):531-540. Go to original source...
    12. Reed AM, Haugen M, P^chman LM, Langman CB. Repair of osteopenia in child­ ren with juvenile rheumatoid arthritis. J Pediatr 1993;122(5 Pt 1):693-696. Go to original source...
    13. Reeve J, Loftus J, Hesp R, Ansell BM, Wright DJ, Woo PM. Biochemical predic­ tion of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993;20(7):1189-1195.
    14. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN et al. Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40(11):1967-1975. Go to original source...
    15. Lien G, Flato B, Haugen M, Vinje O, Sorskaar D, Dale K et al. Frequency of oste­ openia in adolescents with early-onsetjuvenile idiopathic arthritis: a long-term o come study of one hundred five patients. Arthritis Rheum 2003;48(8):2214-2223. Go to original source...
    16. Haugen M, Lien G, Flato B, Kvammen J, Vinje O, Sorskaar D et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum 2000;43(7):1504-1510. Go to original source...
    17. Hopp R, Degan J, Gallagher JC, Cassidy JT. Estimation of bone mineral density in children withjuvenile rheumatoid arthritis. J Rheumatol 1991;18(8):1235-1239.
    18. Lien G, Selvaag AM, Flato B, Haugen M, Vinje O, Sorskaar D et al. A two-year prospective controlled study of bone mass and bone turnover in children with ear­ ly juvenile idiopathic arthritis. Arthritis Rheum 2005;52(3):833-840. Go to original source...
    19. French AR, Mason T, Nelson AM, Crowson CS, O'Fallon WM, Khosla S et al. Osteopenia in adults with a history ofjuvenile rheumatoid arthritis. A population based study. J Rheumatol 2002;29(5):1065-1070.
    20. Zak M, Hassager C, Lovell DJ, Nielsen S, Henderson CJ, Pedersen FK. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study. Arthritis Rheum 1999;42(4): 790-798. Go to original source...
    21. Murray K, Boyle RJ, Woo LP al. e. Pthological fractures and osteoporosis in a hort of 103 systemic onset juvenile idiopathic arthritis patients Arthritis Rheum 2000;43(Suppl):S119.
    22. Roth J, Palm C, Scheunemann I, Ranke MB, Schweizer R, Dannecker GE. Musculoskeletal abnormalities of the forearm in patients with juvenile idiopathic arthritis relate mainly to bone geometry. Arthritis Rheum 2004;50(4):1277-1285. Go to original source...
    23. Burnham JM, Shults J, Sembhi H, Zemel BS, Leonard MB. The dysfunctional muscle-bone unit in juvenile idiopathic arthritis. J Musculoskelet Neuronal Interact 2006;6(4):351-352.
    24. Lindehammar H, Lindvall B. Muscle involv Rheumatology (Oxford) 2004;43(12):1546-1554. Go to original source...
    25. Gattorno M, Vignola S, Falcini F, Sabatini F, Buoncompagni A, Simonini G et al. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tis­ sue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002;29(4):826-831.
    26. Ma D, Jones G. Television, computer, and video viewing; physical activity; and upper limb fracture risk in children: a population-based case control study. J Miner Res 2003;18(11):1970-1977. Go to original source...
    27. Goulding A, Jones IE, Taylor RW, Williams SM, Manning PJ. Bone mineral den­ sity and body composition in boys with distal forearm fr ray absorptiometry study. J Pediatr 2001;139(4):509-515. Go to original source...
    28. Felin EM, Prahalad S, Askew EW, Moyer-Mileur LJ. Musculoskeletal abnormali­ ties of 984-994.
    29. Hillman L, Cassidy JT, Johnson L, Lee D, Allen SH. Vitamin D metabolism and bone mineralization 1994;124(6):910-916.
    30. Gorska A, Urban M, Bartnicka M, Zelazowska-Rutkowska B, Wysocka J. Bone mineral metabolism in children with juvenile id port. Ortop Traumatol Rehabil 2008;10(1):54-62.
    31. Goldring SR. Pthogenesis of bone and cartilage destruction in rheumatoid arth tis. Rheumatology (Oxford) 2003;42 Suppl 2:ii11-6. Go to original source...
    32. Pereira RM, Falco V, Corrente JE, Chahade WH, Yoshinari NH. Abnormalities in the biochemical markers of bone turnover in children withjuvenile chronic arthri­ tis. Clin Exp Rheumatol 1999;17(2):251-255.
    33. Sullivan KE. Inflammation in juvenile idiopathic arthritis. Pediatr Clin N 2005;52(2):335-57. Go to original source...
    34. Agarwal S, Misra R, Aggarwal A Synovial fluid RANKL and matrix metallopro­ teinase levels in enthesitis related arthritis subtype ofjuvenile idiopathic arthrit Rheumatol Int 2009;29(8):907-911. Go to original source...
    35. Krane SM, Inada M. Matrix metalloproteinases and bone. Bone. 2008;43(1):7-18. Go to original source...
    36. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995;270(11):5872-5876. Go to original source...
    37. Peake NJ, Foster HE, Khawaja K, Cawston TE, Rowan AD. Assessment of the cli­ nical significance of gelatinase activity in patients with juvenile idiopathic a tis using quantitative protein substrate zymography. Ann Rheum Dis 2006;65(4): 501-507. Go to original source...
    38. Sarma PK, Misra R, Aggarwal A Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 2008;27(3):289-294. Go to original source...
    39. Peake NJ, Khawaja K, Myers A, Jones D, Cawston TE, Rowan AD et al. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 sue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology (Oxford) 2005;44(11):1383-1389. Go to original source...
    40. Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorpti toid arthritis. Rheumatology (Oxford) 2004;43 Suppl 3:iii10-iii6. Go to original source...
    41. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation activation. Cell. 1998;93(2):165-176. Go to original source...
    42. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/oste inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-3602. Go to original source...
    43. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M et al. TRANCE is a no­ vel ligand of the tumor necrosis factor receptor family that activates c-Jun Nminal kinase in T cells. J Biol Chem 1997;272(40):25190-25194. Go to original source...
    44. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96(7):3540-3545. Go to original source...
    45. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast dif rentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139(10): 4424-4427. Go to original source...
    46. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998;246(1):199-204. Go to original source...
    47. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone den­ sity. Cell 1997;89(2):309-319. Go to original source...
    48. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15(1):2-12. Go to original source...
    49. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W et al. High levels of osteoprotegerin and soluble receptor acti­ vator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthr Rheum 2002;46(7):1744-1753. Go to original source...
    50. Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? J Rheumatol 2004;31(5):986-991.
    51. Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K et al. RANKL:osteoprotegerin ratio and bone mineral density in children with unt­ reated juvenile dermatomyositis. Arthritis Rheum 2007;56(3):977-983. Go to original source...
    52. Spelling P, Bonfa E, Caparbo VF, Ibreira RM. Osteoprotegerin/RANKL system imbalance in active polyarticular-onsetjuvenile idi ge biomarker? Scand J Rheumatol 2008;37(6):439-444. Go to original source...
    53. Viswanathan A, Sylvester FA Chronic pediatri bone. Rev Endocr Metab Disord 2008;9(2):107-122. Go to original source...
    54. Falcini F, Ermini M, Bagnoli F. Bone turnover is reduced in children with juve le rheumatoid arthritis. J Endocrinol Invest 1998;21(1):31-36. Go to original source...
    55. Li Y, Li A, Strait K, Zhang H, Nanes MS, Weitzmann MN. Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J Bone Miner Res 2007;22(5):646-655. Go to original source...
    56. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al. Dickkopf1 is a master regulator ofjoint remodeling. Nat Med 2007;13(2):156-163. Go to original source...
    57. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006;7(1-2):33-39. Go to original source...
    58. Krishnan V, Bryant HU, Macdougald OA Regulation of bone mass by Wnt sig­ naling. J Clin Invest. 2006;116(5):1202-1209. Go to original source...
    59. Glass DA, 2nd, Bialek P, Ahn JD, Starbuck M, Ptel MS, Clevers H et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast diff tiation. Developmental cell 2005;8(5):751-64. Go to original source...
    60. Lamb R, Thomson W, Ogilvie E, Donn R. Wnt-1-inducible signaling pathway protein 3 and susceptibility to juvenile idiopathic arthritis. Arthritis Rheum 2005;52(11):3548-3553. Go to original source...
    61. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332(5):305-311. Go to original source...
    62. Rouster-Stevens KA, Klein-Gitelman MS. Bone health in pediatric rheumati sease. Curr Opin Pediatr 2005;17(6):703-708. Go to original source...
    63. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited b osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46(3):785-792. Go to original source...
    64. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-indu osteoclastogenesis. J Clin Invest 2005;115(2):282-290. Go to original source...
    65. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J 1987;138(3):775-779. Go to original source...
    66. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 2003;544:181-196. Go to original source...
    67. Nanes MS. Tumor necrosis factor-alp skeletal pathology. Gene 2003;321:1-15. Go to original source...
    68. Smith BJ, Lerner MR, Bu SY, Lucas EA, Hanas JS, Lightfoot SA et al. Systemic bone loss and induction of coronary vessel disease in a rat model of chroni flammation. Bone 2006;38(3):378-386. Go to original source...
    69. Kwan Tat S, Phdrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15(1):49-60. Go to original source...
    70. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteocl ce of osteoblasts/stromal cells. Exp Cell Res 1999;247(1):84-93. Go to original source...
    71. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthriti Rev Immunol 2007;7(6):429^42. Go to original source...
    72. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25: 821-852. Go to original source...
    73. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destr 2005;7(1):29-37. Go to original source...
    74. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator osteoclastogenesis. J Clin Invest 1999;103(9):1345-1352. Go to original source...
    75. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK et al. IL-17 promotes bone erosion in murine colla­ gen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170(5):2655-2662. Go to original source...
    76. Bianchi ML. Glucorticoids and bone: some general remarks and some special ob­ servations in pediatric patients. Calcif Tissue Int 2002;70(5):384-390. Go to original source...
    77. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005;3(3):98-102. Go to original source...
    78. Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhoo te lymphoblastic leukemia. J Clin Oncol 2004;22(7):1215-1221. Go to original source...
    79. Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR et al. The effect of low dose methotrexate on bone density. J Rheumatol 2001;28(11):2395-2399.
    80. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory j Rheum Dis 2003;62(3):245-247. Go to original source...
    81. Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005;44(6):777-780. Go to original source...
    82. Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepuberta pathic arthritis. J Rheumatol 2007;34(12):2481-2485.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.